Trends and determinants of prevalence, awareness, treatment and control of dyslipidaemia in canton of Geneva, 2005–2019: Potent statins are underused

Marques‐Vidal, Pedro; Chekanova, Valeriya; Mestral, Carlos de; Guessous, Idris; Stringhini, Silvia

doi:10.1016/j.ijcrp.2023.200187

Cited by 1 publication

(1 citation statement)

References 53 publications

(65 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Marques-Vidal et al performed a population-based cross-sectional study of adults in Geneva, Switzerland, in which the medications used by individuals to treat dyslipidemia were determined in the period from 2005 to 2019 [16]. This study was based on yearly health examination surveys and data on about 10 000 individuals.…”

Section: Discussionmentioning

confidence: 99%

National Trends in the Use of State-Reimbursed Lipid-Lowering Medications in Latvia (2012–2021)

Praskilevics,

Urtane,

Latkovskis

2023

JCM

View full text Add to dashboard Cite

Background. We aimed to estimate the trends in dispensing rate and the spectrum of all state-funded lipid-lowering medications (LLMs) in Latvia over a decade. Methods. Using data from the National Health Service of the Republic of Latvia, we retrospectively analyzed all dispensed LLM-containing drug units in a ten-year period from 2012 to 2021. Results. In Latvia, 318.2 million oral and 994 subcutaneous units of LLMs were dispensed over a decade. Statins were the most dispensed LLMs (94.5%), and their use doubled from 19.7 to 43.5 million units. The proportion of high-intensity statins increased from 31.3% to 45.2%. The dispensing rate of ezetimibe increased from 184.7 thousand to 4.8 million. The share of fixed-dose statin combinations with ezetimibe grew from 0.2% to 10.0% among all statins and from 22.2% to 90.9% among all ezetimibe units. Statin use for primary and secondary prevention increased from 7.0 to 19.9 million and from 12.8 to 23.6 million units, respectively. Conclusion. The dispensing rate of statins doubled, and the use of ezetimibe increased more than 25 times in Latvia over a decade. The proportion of high-intensity statins increased from one third to almost half of all statins. Fixed-dose statin combinations with ezetimibe became frequently used.

show abstract

Section: Discussionmentioning

confidence: 99%